These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28160058)

  • 1. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Strupas K
    Langenbecks Arch Surg; 2017 Mar; 402(2):227-234. PubMed ID: 28160058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combined Use of Fine-Needle Aspiration (FNA) and BRAF V600E Gene Testing: Can it Increase the Definitive Diagnosis Rate of Nodules Categorized as Bethesda III for Papillary Thyroid Carcinoma?
    Lei L; Hong Qing S; Wei L; Ma Mo Yang F; Xiao Xiang Y
    Am Surg; 2024 Dec; 90(12):3209-3215. PubMed ID: 39047144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
    Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
    Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
    Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.
    Zha X; Miao Z; Huang X; Wang X; Xie R; Jin J; Zou D; Yang P; Huang Y
    Front Endocrinol (Lausanne); 2022; 13():822423. PubMed ID: 35197932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
    Li W; Sciallis A; Lew M; Pang J; Jing X
    Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Fine Needle Aspiration, the Bethesda System, and the BRAFV600E Mutation in Papillary Thyroid Carcinoma: Association and Prediction for Biopsy.
    Galán-García ME; Martínez-Martin MS; Araujo-Ruano EJ; Loro-Ferrer JF; Saavedra-Santana P; Salido-Ruiz E; Cabrera-Galván JJ
    Acta Cytol; 2023; 67(4):346-356. PubMed ID: 36592623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of the detection of
    Zhao H; Guo HQ; Zhang ZH; Cao J; Zhao LL; Sun Y; Wang C; Xiao T
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):18-22. PubMed ID: 30704164
    [No Abstract]   [Full Text] [Related]  

  • 12. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
    Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
    Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH; Kim BS; Kang KH; Kim HS
    World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
    Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
    Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Subcategory Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Showing Both Cytologic and Architectural Atypia in Thyroid Aspiration Cytology.
    Jung YY; Jung S; Lee HW; Oh YL
    Acta Cytol; 2015; 59(5):370-6. PubMed ID: 26529329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
    Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
    Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
    Arva NC; Deitch SG
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.